Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study

The information in the press release is intended for investors.

Dr. Roger Tell (MD, PhD) has been active at Isofol in various roles since 2019; as Senior Vice President of Clinical Development, Chief Scientific Officer, Chief Medical Officer as well as acting Chief Executive Officer, CEO. Roger Tell has a background as a clinical oncologist at Karolinska Institutet and served in several international roles in pharmaceutic companies like Servier and Aprea Therapeutics as well as advisor for Eli Lilly, Astra Zeneca and Merck Serono.

For the last two years, Roger Tell has been working for Isofol on a consultancy basis, but ahead of the initiation of a new clinical study of arfolitixorin, he returns to a permanent position, effective immediately.

“We are looking to the future with confidence and are by this expanding our organization with an additional employee in the management team. I have great confidence in Roger as Chief Medical Officer and by re-employing him we are building an organization for the long term, securing the competence and continuity required to run our clinical study in an optimal way,” says Petter Segelman Lindqvist, CEO of Isofol.

“The new data for arfolitixorin that we were able to present last year has further strengthened my confidence in the project and in Isofol’s strategy, and I look forward to running the clinical study that is expected to begin in the spring,” says Roger Tell, Chief Medical Officer of Isofol.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 3, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with new dosage regimens that are expected to optimize the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com